📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis (2022)

First Author: Harrison C

Attributed to: The Oxford Single Cell Biology Consortium funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2217/fon-2022-0484

PubMed Identifier: 35950489

Publication URI: http://europepmc.org/abstract/MED/35950489

Type: Journal Article/Review

Parent Publication: Future Oncology

Issue: 27

ISSN: 1479-6694